Affimed reported positive results in various cancer treatments trials, maintaining strong financial position.
From “GlobeNewswire”: 2024-09-05 06:30:00 Afimed N.V. reported promising results from AFM24 combination with atezolizumab for EGFRmut NSCLC patients: 1 CR,